TL;DR
Surgeons at Huashan Hospital in Shanghai have performed the world’s first surgery using a commercially approved brain-computer interface, implanting Neuracle’s coin-sized NEO device in a patient who lost hand function to a spinal-cord injury. The angle: China beat Neuralink to the commercial finish line by choosing a deliberately more modest device, one that rests on the brain’s surface rather than piercing it, and got it approved, insured and into a patient in four months. It is the commercialisation-over-ambition pattern applied to neurotech.
China has performed the world’s first surgery using a commercially approved brain-computer interface. Surgeons at Huashan Hospital in Shanghai implanted a coin-sized chip in a patient with impaired hand movement, the South China Morning Post reports.
The patient had lost hand function after a spinal cord injury in a car accident a decade ago. The procedure captured stable brain signals, and the person is recovering with steady vital signs.
The milestone is real, and so is the caveat. China got here by building a more modest device than the one Neuralink is chasing.
What NEO actually is
The device is called NEO, made by the Shanghai start-up Neuracle Medical Technology. It is roughly the size of a coin and carries eight electrodes.
Crucially, it does not go into the brain. NEO rests on the outer surface and reads neural signals through the protective membrane, without piercing cortical tissue.
That is the key difference from Neuralink, whose implant threads electrodes directly into the brain. NEO captures less detail, but it is lower-risk and far easier to get approved.
Commercial, not experimental
The word that matters here is commercial. NEO won approval from China’s National Medical Products Administration in March, making it a prescribable product rather than a research device.
What happened next is the actual story. In four months, NEO moved through production, hospital rollout, patient screening, and into local commercial health insurance.
That is a speed of productisation Western neurotech has not matched. It looks like the same commercialisation engine driving China’s lead elsewhere, now pointed at the brain.
How it compares to Neuralink
Neuralink is more ambitious and less finished. It has implanted its device in more than 20 trial patients, aiming to let people with paralysis control computers and robotic limbs by thought.
But it has no full commercial approval from the US FDA. Musk’s company is building the more powerful implant, while China has shipped the approvable one, a point underlined when Beijing cleared NEO for commercial use back in March.
The invasive field is crowded now, with Paradromics putting a brain chip in its first patient and Science Corp preparing its own human placement. NEO’s distinction is not raw capability, it is that a paying patient can actually get one.
The state behind it
None of this happened by accident. Beijing has named brain-computer interfaces a strategic future industry and wants two or three global leaders by 2030.
A government blueprint last year set breakthrough targets for 2027, and Neuracle is already moving toward a Shanghai stock listing. The approval, the insurance coverage, and the funding are all arms of the same push.
China is also running the non-invasive track in parallel, with wearable headsets aimed at the mass market rather than the operating theatre. The invasive and the everyday are being pursued at once.
The part worth watching
A lower-risk surface implant is easier to approve, but it is also a smaller promise. NEO restores a slice of hand function, not the sweeping control of devices that the field’s biggest claims describe.
There are hard questions coming, about neural-data privacy and about how far a consumer-facing version should go. Some in the field want firm limits, with Neuralink rival Inbrain vowing never to take brain implants beyond healthcare.
For now, though, the scoreboard is simple. A Chinese patient has a working, insured, commercially approved brain implant, and no American one does.
